Nutrition Giant GNC To Distribute CBD Products In 770 Stores In US – Benzinga – Benzinga
Hemp cannabidiol (CBD) products maker CV Sciences, Inc. (OTCQB:CVSI) has signed a distribution agreement with health and nutrition-related products behemoth GNC.
Beginning in early 2022, consumers will be able to purchase CVSI’s ingestible products under the +PlusCBD brand in 770 GNC locations. The initial product lineup will include:
“We are thrilled to partner with GNC, a leading global health and wellness brand, and view this agreement as a major milestone in our distribution expansion strategy as well as a strong testament to the safety and efficacy of CV Sciences’ portfolio of high-quality products,” said Joseph Dowling, CEO of CV Sciences. “This agreement is also a positive reflection of the favorable regulatory momentum that is starting to build following the recent passage of AB 45 in California, which should serve as a framework for responsible CBD legislation in other states and eventually at the federal level.”
Más contenido sobre cannabis en Español en El Planteo.
For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In:
Alan Brochstein’s 420 Investor is the go-to community for investors to learn, explore, and profit from the marijuana companies. The main goal of 420 Investor is to provide real-time, objective information about the top marijuana companies in the market in order to help investors capitalize on cannabis.
We’re an experienced team that is looking for a smart, driven, self-starter who has a high-level awareness to anticipate things that need to be done or comes up with new ideas to improve the product experience for our users.
Never miss out on the breaking news in the Cannabis Industry!
© 2022 Benzinga | All Rights Reserved
Advertiser Disclosure: TD Ameritrade, Inc. and Accretive Capital LLC are separate, unaffiliated companies and are not responsible for each other’s services and products.
Editorial Disclosure: Reviews are as determined by Benzinga Money. Opinions expressed here are solely the author’s and have not been reviewed, approved or otherwise endorsed by reviewers.
